Inside Spark Therapeutics' Investigational SPK-8011 For Hemophilia A With Dr. Tiffany Chang
Source: Cell & Gene

Spark Therapeutics' Clinical Development Lead, Hematology, Dr. Tiffany Chang explains the company's data from its ongoing Phase 1/2 clinical trial of investigational SPK-8011 for hemophilia A, the largest gene therapy trial in this disease to date as well as the misconceptions and unknowns about the disease.
This website uses cookies to ensure you get the best experience on our website. Learn more